In our study, two clinics that together contributed 97 TSC patient DNA samples are referral centers for epilepsy treatment, which might lead to a higher recruitment of severe, refractory epilepsy cases and therefore a higher rate of mutation detection as well as a preponderance of pathogenic TSC2 variants [12,51,52]. The gene discussed is TSC2; the disease is tuberous sclerosis.